Fairness opinions › Segments
Pharmacy / Infusion fairness opinions
5 public-company healthcare transactions in Pharmacy / Infusion, 2015-2025, each with the banker's fairness opinion from the SEC filing: the DCF discount rate and terminal assumptions, the selected companies and precedent transactions, and the deal terms.
Valuation benchmarks
EV / LTM EBITDA
12.1x
median · n=5
EV / LTM revenue
0.49x
median · n=5
DCF discount rate (midpoint)
8.7%
median · n=5
Pharmacy / Infusion transactions with a fairness opinion, 2015-2025. Multiples are enterprise value over the last-twelve-months figure disclosed in the filing; the discount rate is the midpoint of the range the banker used in its DCF.
Bankers most often engaged in Pharmacy / Infusion
Centerview Partners (3) · BofA Securities (2) · Morgan Stanley (1) · Allen (1) · Barclays (1) · Goldman Sachs (1) · UBS (1)
All Pharmacy / Infusion transactions
| Announced | Target | Acquirer | EV | EV/EBITDA | EV/Rev | DCF rate | Fairness opinion |
|---|---|---|---|---|---|---|---|
| 2025-03-06 | Walgreens | Sycamore Partners | $24B | 52.4x | 0.16x | 9.3%–10.8% | Centerview Partners, Morgan Stanley |
| 2019-12-09 | Diplomat Pharmacy | UnitedHealth Group | $898M | 12.1x | 0.18x | 10.5% | |
| 2017-12-03 | CVS Health | Aetna | $90B | 7.2x | 0.49x | 7.0%–8.5% | Allen, Barclays, Goldman Sachs, Centerview Partners |
| 2017-08-02 | PharMerica | KKR | $1.4B | 9.6x | 0.60x | 8.0%–9.0% | UBS, BofA Securities |
| 2015-05-21 | Omnicare | CVS Health | $12B | 15.8x | 1.87x | 8.0%–9.5% | Centerview Partners, BofA Securities |
3,000+ healthcare deal-level valuation multiples
The Valuation database includes financial details for more than 3,000 healthcare M&A transactions, private and public, with deal-level multiples, categorized by segment, type, and year.